The EAEU GVP Rules do not mention the CIOMS I form. Which format and deadline apply to reports from publications


The registration holder should review the scientific medical literature at least once a week. This is provided for by the Good Pharmacovigilance Practice (GVP) Rules of the Eurasian Economic Union, approved by Decision of the Council of the Eurasian Economic Commission (EEC) No. 87 of 3 November 2016 (hereinafter the GVP Rules).
The registration holder submits to the authorized body a report of a serious adverse reaction identified in a member state, and of a serious unexpected reaction identified in the territories of other states, within 15 calendar days from the date of receiving the minimum required information under the GVP Rules. The minimum required information consists of details of the reporter, the patient, the suspected medicinal product and the suspected adverse reaction.
Individual case safety reports are submitted electronically in E2B format, that is, the format for transmitting information on an individual case of an adverse reaction. The CIOMS I form (a blank form for reporting an individual case of an adverse reaction) is mentioned neither in the GVP Rules nor in the Pharmacovigilance Procedure approved by Order of the Federal Service for Surveillance in Healthcare (Roszdravnadzor) No. 3518 of 17 June 2024 (hereinafter the Pharmacovigilance Procedure).

Regulatory acts on literature monitoring

ActWhat it sets on the topic of the article
GVP Rules (Decision of the EEC Council No. 87 of 3 November 2016, as amended on 19 May 2022)Literature search, selection of publications, minimum information on a case, deadlines, report format
Federal Law No. 61-FZ «On the Circulation of Medicines» (as amended on 4 August 2026)The obligation to report adverse reactions identified in Russia and in other states; measures on identifying serious and unexpected reactions; liability for failure to report
Pharmacovigilance Procedure (Roszdravnadzor Order No. 3518 of 17 June 2024)The channel for sending reports; the requirement for the registration holder’s pharmacovigilance system
Guideline on Ensuring Data Integrity and Validation of Computerized Systems (Recommendation of the EEC Board No. 25 of 19 September 2023)Voluntary application in the field of good pharmacovigilance practice

The GVP Rules form part of Union law. Under Federal Law No. 61-FZ, pharmacovigilance in Russia is conducted taking into account the acts that make up Union law. Under the Pharmacovigilance Procedure, the registration holder’s pharmacovigilance system must comply with the GVP Rules.

How the literature search is structured

ParameterWhat the GVP Rules set
FrequencyA systematic review at least once a week
DatabasesWidely used reference databases, including Medline and Embase; the review covers the databases with the largest number of references to articles on the monitored product
Local journalsAll representative offices of the registration holder know of publications in local medical journals and report them to the registration holder’s safety department
Types of publicationsReports of suspected adverse reactions, including those in conference proceedings and draft monographs; they are recorded as spontaneous reports or as reports from non-interventional post-registration studies
GeographyPublications in all states where the product is approved for use
Several products in one publicationProducts that the authors identify as having at least a possible causal relationship with the reaction are considered
Primary sourceThe first author of the publication; data on co-authors need not be documented as primary source information
Unit of recordingOne case per identifiable patient; a publication with several patients gives as many reports as the publication describes patients
ContractorDetailed written agreements allocating responsibilities and enabling the registration holder to meet the reporting requirements

The requirements for review and monitoring use the word «should»; the words «must» and «shall» do not appear in them. The phrase «including» makes the list of databases open: Medline and Embase are named as examples.
The search for a periodic safety update report (PSUR) is broader than the search for individual cases. It includes studies in which the outcomes of adverse reactions are assessed in groups of subjects.

When a publication yields a case that must be reported

Only individual reports of adverse reactions that have passed validation against the minimum required information are subject to expedited reporting.
The minimum information includes four elements:
Reporter (primary source). At least one reporter is identified by such parameters as qualifications, name, initials or location. Information from a third party who has no direct contact with the patient is not considered valid until the patient, the treating physician or a reporter with such contact confirms it. For a publication, the first author is considered the primary source.
Patient. One characteristic is sufficient: initials, medical record number, date of birth, age or age group, gestation period or sex.
Suspected medicinal product or active substance. Interacting products are classed as suspected.
Suspected adverse reaction.

A report on several patients is invalid if it contains no information on at least one patient characteristic.
The GVP Rules name three cases in which a reaction report is invalid:
the primary source explicitly rules out a causal relationship between the product and the reaction, and the recipient of the report agrees;
the report states that the patient experienced a reaction, but the type of reaction is neither named nor described;
only information on the outcome is available, and follow-up data collection fails to obtain a clinical justification of the reaction as the cause of the outcome, or the primary source has not indicated at least a possible link with taking the product.

If any of the four elements is missing, the case is considered incomplete and is not subject to expedited submission. Incomplete reports are recorded in the pharmacovigilance system, and the actions to collect the missing information are documented. Once the missing data are obtained, the report is assessed as valid and is subject to reporting.

Which publications are not subject to expedited reporting

The GVP Rules list six cases in which reports identified in monitoring publications are not subject to expedited reporting.

Case
The product can be excluded as the registration holder’s by the trade name, active substance, dosage form, route of administration and batch number given in the report
The product can be excluded as the registration holder’s by the country of the primary source or the country where the reaction occurred, if the registration holder did not supply the product to that territory
The publication contains the result of an analysis by an authorized body of an adverse reaction database. The exclusion does not extend to publications based on analyses of databases of other authorized bodies
The publication contains information from publicly accessible databases, with cases presented in tables or line listings. The exclusion does not extend to publications from which a valid report can be prepared
The publication presents the results of post-registration studies, meta-analyses or scientific reviews
The publication describes reactions in a group of patients in connection with the use of a particular product; there are no individual data for a valid report

Safety information from publications not subject to expedited reporting is considered in the relevant sections of the PSUR and taken into account in analyzing the benefit-risk balance of the product. The authorized body of the member state where the product is registered should be notified without delay of any new safety information that may affect this balance.

Which reports are submitted within 15 calendar days and from which day the deadline runs

The registration holder submits to the authorized body of the member state, within 15 calendar days from the date when the registration holder or its authorized representative receives the minimum required information:
a report of a serious adverse reaction identified in the territory of a member state;
a report of a serious unexpected adverse reaction identified in the territories of other states.

The deadline applies to initial and additional information. A serious expected reaction identified in the territories of other states is not named in this list.
For cases from the literature, day zero, from which the deadline runs, falls on the date of notification of a publication that contains the minimum required information. When significant additional information is received, the deadline for a follow-up report is counted anew from the date of its receipt. Information is considered significant if it is new medical or administrative information that may affect the assessment or management of the case or change its assessment against the seriousness criteria. Non-significant information includes updated comments on the assessment and corrections of grammatical and punctuation errors.

In what format a report is submitted and how the CIOMS I form relates to it

Individual case safety reports are submitted to the authorized body electronically in the E2B format defined in the guideline of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, «Clinical Safety Data Management: Data Elements for Transmission of Individual Case Safety Reports». The GVP Rules provide for a transition from version R2 to version R3.
A report uses MedDRA terminology (the Medical Dictionary for Regulatory Activities), and the terms must be at the lowest level (LLT). The registration holder ensures that the recommendations of the organization that maintains MedDRA are followed, for a timely transition to new versions of the dictionary.
For a report published in the literature, the GVP Rules set three requirements:
the E2B section «Literature Reference» is completed, stating the digital object identifier (DOI) of the publication;
a detailed description of the case is included in the section «Case Narrative, Including Clinical Course, Therapeutic Measures, Outcome and Additional Relevant Information»;
a copy of the publication (and a translation, if applicable) is provided at the request of the authorized body when a review of safety information is needed, with regard to copyright legislation, and is included in the section «Attached Documents». If the copy is provided separately from a previously sent report, the original report with the attached document is submitted again under the procedure for amending an individual case safety report.

The word «CIOMS» does not appear in the GVP Rules as amended on 19 May 2022 or in the Pharmacovigilance Procedure. These acts contain no provisions on the use of the CIOMS I form, including inside a company.

What Federal Law No. 61-FZ and the Pharmacovigilance Procedure establish

Participants in the circulation of medicines must, under the procedure set by the authorized federal executive body, report to that body adverse reactions and other facts and circumstances that threaten the life or health of a person or animal and are identified at all stages of the circulation of medicinal products in the Russian Federation and other states. When information is identified on serious and unexpected adverse reactions, on features of the interaction of products with other medicinal products, on individual intolerance and on other facts that affect the balance between the expected benefit and the possible risk, the registration holder must take measures to eliminate the negative consequences of using the product, prevent harm to life or health, protect against the use of such a product and collect additional data on efficacy and safety. This obligation also applies to legal entities in whose names permits to conduct clinical trials have been issued, and to other legal entities authorized by them.
For failure to report or for concealing information that participants in the circulation of medicines are required to report, the registration holder, the legal entities in whose names permits to conduct clinical trials have been issued, other legal entities authorized by them, and officials who learned of this information in the course of their professional activities are liable under the legislation of the Russian Federation. The liability provision of Federal Law No. 61-FZ does not name the measure of liability.
The Pharmacovigilance Procedure is in effect from 1 March 2025 until 1 March 2031. Orders of Roszdravnadzor No. 1071 of 15 February 2017 and No. 6252 of 16 July 2020 were declared no longer in force by Roszdravnadzor Order No. 3518.
Reports are sent through the Roszdravnadzor AIS, that is, the automated information system of Roszdravnadzor. If technical problems occur in the Roszdravnadzor AIS, reports are sent to pharm@roszdravnadzor.gov.ru. If technical problems occur in the registration holder’s databases, reports are sent to the same address, stating the expected dates for resuming the operation of the databases. After operation is restored, the registration holder enters these reports into the Roszdravnadzor AIS. For products registered in the Russian Federation and products whose circulation is permitted by legislation, except products for clinical trials, a report by e-mail is drawn up as a notification of an adverse reaction or lack of therapeutic effect, following the recommended template from the Pharmacovigilance Procedure.
The Pharmacovigilance Procedure sets reporting deadlines for medical organizations. For the registration holder, the 15-calendar-day deadline is set by the GVP Rules. The word «literature» does not appear in the Pharmacovigilance Procedure.

What to do

Set out the literature search procedure in an SOP (standard operating procedure). Include a weekly search; databases, among them Medline, Embase and the databases with the largest number of references for each product; a list of local journals; and a search of publications from all states where the product is approved for use.
Record day zero. Write down the date of notification of a publication that contains the minimum information. If a contractor performs the search, conclude a written agreement allocating responsibilities and set in it a deadline for forwarding the publication to the registration holder, leaving a margin within the 15 calendar days.
Review each publication in two steps. First check the four elements of the minimum information, then the six exclusions. Record incomplete cases and document the requests for the missing data. Pass information from publications not subject to expedited reporting to the preparation of the PSUR.
Prepare the report in E2B(R3) format. Draw up one case per patient, code MedDRA terms at the LLT level, state the DOI of the publication and attach a copy at the request of the authority. Send the report through the Roszdravnadzor AIS. The GVP Rules and the Pharmacovigilance Procedure do not provide for the CIOMS I form for a report to the authorized body.
Describe computerized systems in the master file. The pharmacovigilance system master file (a document describing the registration holder’s pharmacovigilance system) must describe the location, functionality and responsibility for operating computerized systems and databases. If there are several systems, the description covers their applicability to pharmacovigilance, the validation status of the main aspects of their functionality, as well as change control, the structure of testing, backup procedures and electronic data archives needed to meet pharmacovigilance requirements. If part of the literature search or of the review of publications is automated, validation can be checked against the Guideline on Ensuring Data Integrity and Validation of Computerized Systems (Recommendation of the EEC Board No. 25), which allows voluntary application in the field of good pharmacovigilance practice.


Regulatory framework:

1. Decision of the Council of the Eurasian Economic Commission No. 87 of 3 November 2016 «On Approval of the Good Pharmacovigilance Practice Rules of the Eurasian Economic Union» (as amended on 19 May 2022)
2. Federal Law No. 61-FZ of 12 April 2010 «On the Circulation of Medicines» (as amended on 4 August 2026)
3. Order of the Federal Service for Surveillance in Healthcare No. 3518 of 17 June 2024 «On Approval of the Procedure for Pharmacovigilance of Medicinal Products for Medical Use» (registered with the Russian Ministry of Justice on 5 September 2024, No. 79394)
4. Recommendation of the Board of the Eurasian Economic Commission No. 25 of 19 September 2023 «On the Guideline on Ensuring Data Integrity and Validation of Computerized Systems»
5. Order of the Federal Service for Surveillance in Healthcare No. 1071 of 15 February 2017 «On Approval of the Procedure for Carrying Out Pharmacovigilance» (declared no longer in force by Order No. 3518 of 17 June 2024, which entered into force on 1 March 2025)
6. Order of the Federal Service for Surveillance in Healthcare No. 6252 of 16 July 2020 «On Amendments to the Procedure for Carrying Out Pharmacovigilance Approved by Order No. 1071 of the Federal Service for Surveillance in Healthcare of 15 February 2017» (declared no longer in force by Order No. 3518 of 17 June 2024, which entered into force on 1 March 2025)

This page in Russian→